Study of Resistance Training Habits in Adults Using GLP-1 Receptor Agonists for Diabetes and Weight Management

What this Trial Is About

Researchers are studying adults who use GLP-1 receptor agonist medications, such as semaglutide, liraglutide, or tirzepatide, for type 2 diabetes or weight management. The study aims to understand how these individuals perform resistance strength training before and after starting their medication. This is important because GLP-1 medications can cause loss of muscle mass, which affects strength and daily functioning, and resistance training is key to maintaining muscle. Participants who have been taking a GLP-1 receptor agonist for at least three months at a stable dose complete a single anonymous online survey. The survey collects self-reported information about their resistance training habits before and after starting the medication, including frequency, duration, intensity, and muscle groups targeted. It also asks about their perceived strength, ability to perform daily tasks, fatigue, quality of life, and barriers or facilitators to resistance training. The study involves no in-person visits, physical tests, or blood draws. Participants complete the survey once, which takes about 10 minutes. All responses are anonymous, and no personal identifiers are collected. Researchers will measure changes in resistance training status before and after medication use and examine how training relates to strength and function. Results will help improve guidance for maintaining muscle health in people using GLP-1 medications.

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists